Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aakaar Medical Technologies's Days Sales Outstanding for the
six
months ended in Mar. 2026 was 139.84.
Aakaar Medical Technologies's Days Inventory for the
six
months ended in Mar. 2026 was 211.34.
Aakaar Medical Technologies's Days Payable for the
six
months ended in Mar. 2026 was 23.51.
Therefore, Aakaar Medical Technologies's Cash Conversion Cycle (CCC) for the
six
months ended in Mar. 2026 was 327.67.
Aakaar Medical Technologies (NSE:AAKAAR) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Aakaar Medical Technologies Cash Conversion Cycle Related Terms
Aakaar Medical Technologies Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aakaar Medical Technologies Cash Conversion Cycle Chart
NSE:AAKAAR vs ABT, SYK, MDT: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, Aakaar Medical Technologies's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aakaar Medical Technologies Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aakaar Medical Technologies's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Aakaar Medical Technologies's Cash Conversion Cycle falls into.
Aakaar Medical Technologies Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Aakaar Medical Technologies's Cash Conversion Cycle for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aakaar Medical Technologies (NSE:AAKAAR) has a Cash Conversion Cycle of 327.67 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Aakaar Medical Technologies and its competitors.
Is Aakaar Medical Technologies' Cash Conversion Cycle too high?
Aakaar Medical Technologies' current Cash Conversion Cycle is 327.67. The Medical Devices & Instruments industry median Cash Conversion Cycle is 158.14. Aakaar Medical Technologies' value of 327.67 is 107.2% above this industry median. Overall, Aakaar Medical Technologies has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Aakaar Medical Technologies' Cash Conversion Cycle compare to ABT and SYK?
Aakaar Medical Technologies' Cash Conversion Cycle of 327.67 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 158.14. Aakaar Medical Technologies' value of 327.67 is 107.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 158.14, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aakaar Medical Technologies's current Cash Conversion Cycle of 327.67 is 107.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Aakaar Medical Technologies and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 158.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aakaar Medical Technologies's current Cash Conversion Cycle is 327.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aakaar Medical Technologies stock overvalued right now?
Aakaar Medical Technologies (NSE:AAKAAR) has a current Cash Conversion Cycle of 327.67. The current Cash Conversion Cycle is 327.67 and 107.2% above the Medical Devices & Instruments industry median of 158.14. Aakaar Medical Technologies' overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Aakaar Medical Technologies (NSE:AAKAAR), the current Cash Conversion Cycle is 327.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aakaar Medical Technologies Ltd is a medical aesthetic company dealing in a wide range of aesthetics & specialized cosmetic products & devices. Its product range includes both Own brands (domestically manufactured products & internationally manufactured devices) and Imported Brands (distribution of imported brands) from countries such as Korea, Spain, Italy, and Austria. It has established a distinctive presence in the medical aesthetic market by exclusively focusing on business-to-business(B2B) channels for product distribution and sales. The company supply its products & devices to dermatologists, plastic surgeons, aesthetic physicians who then sell these products to their end consumers as well as use certain device consumables as part of their treatments.
20GF Score
Get the complete analysis for NSE:AAKAAR
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AAKAAR has been successfully added to your 
